Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227018 · ClinicalTrials.gov registry record · Phase 2
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01227018 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 15 participants.
The verdict
NCT01227018, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. PURPOSE: This phase II trial is studying how well hsp90 inhibitor STA-9090 works as second- or third-line therapy for the treatment of patients with metastatic pancreatic cancer.
Interventions
- PROCEDURE blood draw
- DRUG STA-9090
- RADIATION Radiologic imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227018
The ClinicalTrials.gov registry entry for NCT01227018 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which blood draw is the first listed.
NCT01227018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227018 about?
NCT01227018 is a clinical study titled "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer". RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. PURPOSE: This phase II trial is studying how well hsp90 inhibitor STA-9090 works as second- or third-line therapy for the treatment of patients with me...
What is the current status of trial NCT01227018?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01227018?
The interventions under investigation include: blood draw (PROCEDURE), STA-9090 (DRUG), Radiologic imaging (RADIATION).
Who is sponsoring clinical trial NCT01227018?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.